StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $34 at Raymond James
February 22, 2024 12:00 PM
Raymond James analyst Danielle Brill raised the price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) to $34.00 (from $27.00) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Form 10-K Harmony Biosciences Hold For: Dec 31
February 22, 2024 8:01 AM
Form 8-K Harmony Biosciences Hold For: Feb 22
February 22, 2024 7:46 AM
Harmony Biosciences (HRMY) Tops Q4 EPS by 1c
February 22, 2024 7:36 AM
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
February 22, 2024 7:30 AM
Harmony Biosciences (HRMY) Announces FDA Grants Priority Review for Application For Wakix (Pitolisant) In Pediatric Narcolepsy
February 21, 2024 8:06 AM
U.S. FOOD AND DRUG ADMINISTRATION GRANTS PRIORITY REVIEW TO HARMONY BIOSCIENCES' APPLICATION FOR WAKIX® (PITOLISANT) IN PEDIATRIC NARCOLEPSY
February 21, 2024 8:05 AM
Harmony Biosciences (HRMY) Receives U.S. Food And Drug Administration Orphan Drug Designation For Pitolisant In Prader-willi Syndrome
February 20, 2024 8:05 AM
HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT IN PRADER-WILLI SYNDROME
February 20, 2024 8:05 AM
